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Background: Limited data exist regarding outcomes in patients treated with drug eluting stents for off-label indications. The aim was to evaluate 
clinical outcomes with the off-label use of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in an unbiased cohort. 
Methods: In the drug-eluting stent era, we only used SES from May 2004 to April 2007 and only PES from May 2007 to February 2009 in our 
hospital. The 740 consecutive patients who underwent percutaneous coronary intervention with SES or PES between May 2004 and February 2009, 
and who had follow-up coronary angiography scheduled at the average of 7 months after the procedure were analyzed. The restenosis rate (>50% 
by quantitative coronary angiography), 1-year target lesion revascularization (TLR) and major adverse cardiac events (MACE) including nonfatal MI, 
stroke and death were compared between the off-label use of SES (SES-group: 296 patients, 409 lesions) and PES (PES-group: 159 patients, 215 
lesions), as well as between subgroups with diabetes mellitus (SES-DM and PES-DM, 120 patients and 172 lesions, 73 patients and 99 lesions, 
respectively). Off-label use was defined as follows: restenosis, bypass graft lesion, left main lesion, ostial lesion, bifurcation lesion, CTO lesion, or 
vessel size or length outside of information for use recommendation. 
Results: The SES-group had a lower restenosis rate than the PES-group (40 lesions [9.78%] vs. 46 lesions [21.4%], p<0.01%) and a lower TLR rate 
(28 lesions [0.07%] vs. 28 lesions [0.13%], p=0.01). In contrast, there were no significant differences between the SES-DM and PES-DM regarding 
restenosis (27 lesions [15.7%] vs. 24 lesions [24.2%], p=NS) and TLR (21 lesions [0.12%] vs. 15 lesions [0.15%], p=NS). MACE was similar between 
SES-group and PES-group (6 patients [0.02%] vs. 2 patients [0.01%], p=NS) or between SES-DM and PES-DM (4 patients [0.03%] vs. 1 patients 
[0.01%], p=NS). 
Conclusions: In off-label use, SES were superior to PES in terms of restenosis and TLR, but no such differences were observed in diabetic patients.
